Isoquinoline derivatives

Details Isoquinoline derivatives Isoquinoline derivatives

2006-12-05

2009-11-17

Davis, Zinna N (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S310000, C546S141000, C546S143000

Reexamination Certificate

active

07618985

ABSTRACT:
The invention relates to isoquinoline derivatives having the general Formula Iwherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 1 or 2; R1is H, when Y is NH2; or R1is H, (C1-4)alkyl or halogen, when Y is OH; R2and R3are independently H, (C1-4)alkyl or halogen; R is H or (C1-6)alkyl, optionally substituted with OH, (C1-4)-alkyloxy, (C1-4)alkyloxycarbonyl, (C3-7)cycloalkyl, which may optionally comprise a heteroatom selected from O and S, (C6-10)aryl, (C6-10)aryloxy or a 5- or 6-membered heteroaryl group comprising 1-3 heteroatoms independently selected from O, N and S, each aryl or heteroaryl group being optionally substituted with 1-3 substituents independently selected from (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkylsulfonyl and halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of the isoquinoline derivatives in the treatment of ROCK-I related disorders such as hypertension, atherosclerosis and glaucoma.

REFERENCES:
patent: 2007/0135479 (2007-06-01), Ray
patent: 1 403 255 (2004-03-01), None
patent: 1 541 559 (2005-06-01), None
patent: 1 550 660 (2005-07-01), None
patent: WO 04/000955 (2003-12-01), None
patent: WO 2004/024717 (2004-03-01), None
patent: WO 2006/051290 (2006-05-01), None
Chen, P. et al., “Identification of Novel and Potent Isoquinoline Aminooxazole-Based IMPDH Inhibitors,”Bioorg. Med. Chem. Lett.13, 2003, 1345-1348.
Elliott, R.L., et al., “2-(Aryloxymethyl) Azacyclic Analogues as Novel Nicotinic Acetylcholine Receptor (nAChR) Ligands,”Biorg. Med. Chem. Lett., 6, 1996, 2283-2288.
Hendrickson, J.B., et al., An Efficient Synthesis of Substituted Isoquinolines,J. Org. Chem.48, 1983, 3344-3346.
Hirooka, Y., et al., “Therapeutic Potential of Rho-Kinase Inhibitors in Cardiovascular Diseases,”Am. J. Cardiovasc. Drugs, 5(1), 2005, 31-39.
Hu, E. et al., “Rho Kinase as Potential Therapeutic Target for Cardiovascular Diseases . . . ,”Expert Opinion Ther. Targets, 9(4), 2005, 715-736.
Kende, A.S. et al., “A Regiospecific Synthesis of (±)-Decarbomethoxyaklavinone,”Tetrahedron Lett., 22, 1981, 1779-1782.
McOmie, J.F.W., et al., “3,3″-Dihydroxybiphenyl,”Org. Synth., Collect.vol. V, 1973, 412-414.
Mueller, B. et al., “RHO Kinase, a Promising Drug Target for Neurological Disorders,”Nature Reviews Drug Discovery, 4, 2005, 387-398.
Newman, M.S. et al., “The Conversion of Phenols to Thiophenols via Dialkylthiocarbamates,”J. Org. Chem.31, 1966, 3980-3984.
Robinson, Richard A., “1-Dialkylaminoalkylaminoisoquinolines,”J. Am. Chem. Soc., 69, 1947, 1939-1942.
Wisniewski, K. et al., “Applications of the Mitsunobu Reaction in Peptide Chemistry,”J.Pept. Sc.4, 1998, 1-14.
Wolfe, J.P., et al., “Simple, Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates,”J. Org. Chem.65, 2000, 1158-1174.
Takami, A. et al., “Design and Synthesis of Rho Kinase Inhibitors (I)”,Bioorganic & Medicinal Chemistry, 12(9):2115-2137; XP002309639; ISSN: 0968-0896; Elsevier Science Ltd. GB; (May 1, 2004).
Written Opinion dated Mar. 1, 2007 for International Application No. PCT/EP2006/069392 and International Search Report dated Mar. 1, 2007 for International Application No. PCT/EP2006/069392.

Affiliated with

Also associated with

Rating

Isoquinoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Isoquinoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoquinoline derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4143311